sirolimus

(redirected from Rapamune)
Also found in: Medical.

si·ro·li·mus

 (sə-rō′lə-məs)
n.
An immunosuppressive drug produced by the actinomycete Streptomyces hygroscopicus, C15H79NO13, used in combination with cyclosporine and corticosteroids to prevent rejection of transplanted tissues or organs. Also called rapamycin.

[si-, origin unknown + (tac)rolimus.]
Translations

sirolimus

n sirolimus m, sirolimús m (INN)
Mentioned in ?
References in periodicals archive ?
6 billion in 2015; the loss of exclusivity for Zyvox and Rapamune, as well as the termination of the Spiriva co-promotion collaboration, collectively, down approximately $620 million in 2015; and the performance of Lipitor and BeneFIX, collectively, down approximately $160 million in 2015.
Rapamune (Sirolimus, rapamycin): an overview and mechanism of action.
Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others.
M2 EQUITYBITES-June 1, 2015-Pfizer awarded first ever landmark approval for RAPAMUNE for rare progressive lung disease Lymphangioleiomyomatosis (LAM)
M2 PHARMA-June 1, 2015-Pfizer awarded first ever landmark approval for RAPAMUNE for rare progressive lung disease Lymphangioleiomyomatosis (LAM)
Pfizer's Rapamune, used to prevent rejection in organ transplantation, came from a micro-organism isolated from soil collected in Easter Island in the Pacific Ocean, and penicillin, the first ever antibiotic, comes from a fungus.
In the deal, Wyeth, a subsidiary of Pfizer, has agreed to pay $35 million to settle allegations of improper marketing and promotion of the immunosuppressive drug Rapamune.
In July, the company paid $491 million to resolve a case of one of its subsidiaries, Wyeth, marketing the drug Rapamune for uses unapproved by the Food and Drug Administration.
Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression.
Landsteiner solicito a Cofepris en 2009 la autorizacion para la venta del medicamento Renacept como generico intercambiable del farmaco Rapamune, fabricado entonces por Wyeth, laboratorio que fue adquirido por la trasnacional Pfizer.
Oberbauer R, Hutchison B, Eris J, Arias M, Claesson K, Mota A, Kreis H, Kleinman L, Wang F, Chen J, Revicki DA; Rapamune Maintenance Regimen Study Group (2003).
Other key Wyeth drugs include Enbrel for rheumatoid arthritis, Protonix for heartburn, and Rapamune for transplant patients.